linjc16/ctgov huggingface dataset:
Laparoscopic Cystoscopy Versus Traditional Cystoscopy

Study Overview
=================
Brief Summary
-----------------
The study aimed to compare the use of a transurethral laparoscope to the use of a traditional cystoscope for evaluation of the bladder and ureters at the time of laparoscopic hysterectomy. The hypothesis was that visual inspection of the bladder and ureters can be done safely using a transurethral laparoscope, takes less time than traditional cystoscopy, and is more cost effective than traditional cystoscopy.

Official Title
-----------------
Laparoscopic Cystoscopy Versus Traditional Cystoscopy in Patients Undergoing Minimally Invasive Hysterectomy: A Prospective Comparison Study

Conditions
-----------------
Lower Urinary Tract Injury

Intervention / Treatment
-----------------
* Device: cystoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: any female patient scheduled for a laparoscopic supracervical hysterectomy (LSH) or total laparoscopic hysterectomy (TLH) with or without adnexectomy for benign disease able to comprehend and sign the informed consent form able to provide clean-catch urine specimens able to complete a urinary symptom questionnaire pre- and post-operatively Exclusion Criteria: participants in another research protocol involving an investigational product 30 days before planned randomization pregnant women patients undergoing concomitant incontinence or pelvic support procedures (e.g. transvaginal tape, transobturator tape, pelvic organ prolapse surgery) patients known to have a history of recurrent urinary tract infections
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: transurethral laparoscope<br>These patients had cystoscopy performed with the transurethral laparoscope. | Device: cystoscopy<br> <br> |
| Active Comparator: Traditional cystoscopy<br>These patients had cystoscopy performed with the traditional cystoscope, which is considered to be the gold standard. | Device: cystoscopy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time Required to Perform Procedure (in Seconds) | Time required to perform cystoscopy with a laparoscope or a cystoscope after laparoscopic hysterectomy. | During Procedure (Up to 15 minutes) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cystoscopy, minimally invasive hysterectomy
Laparoscopic Bariatric Surgery: Two Regimens of Venous Thromboprophylaxis: Prospective Randomized Study

Study Overview
=================
Brief Summary
-----------------
Obese patients undergoing bariatric surgery warrant VTE prophylaxis because they are at high risk for developing a fatal pulmonary embolism or postthrombotic syndrome. However, a consensus does not exist on the most effective prophylactic approach.

Detailed Description
-----------------
Two regimens of prophylaxis are supposed , the 1st one is to give enoxaparin 40mg 2 hours before surgery and continued daily for 10 days after, and the 2nd one is to start 12 hours before surgery and continued in the same way like the 1st one.

Official Title
-----------------
Laparoscopic Bariatric Surgery: Two Regimens of Venous Thromboprophylaxis: Prospective Randomized Study

Conditions
-----------------
Morbid Obesity, Pulmonary Embolism

Intervention / Treatment
-----------------
* Drug: Enoxaparin 40 mg 2 hours before arm
* Drug: Enoxaparin 40 mg 12 hours before arm


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI >40 OR >35 with comorbidities Exclusion Criteria: No
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: ENOXAPARIN 2 HOURS BEFORE<br>Giving 40 mg enoxaparin SQ 2 hours before surgery and daily for 10 days thereafter | Drug: Enoxaparin 40 mg 2 hours before arm<br>* Enoxaparin 40 mg 2 hours before surgery<br>* Other names: First group;Drug: Enoxaparin 40 mg 12 hours before arm<br>* Enoxaparin 40 mg 12 hours before surgery<br>* Other names: second group;|
| Active Comparator: Enoxaparin 40 mg 12 hours before<br>Enoxaparin 40 mg 12 hours before surgery and once daily for 10 days thereafter | Drug: Enoxaparin 40 mg 2 hours before arm<br>* Enoxaparin 40 mg 2 hours before surgery<br>* Other names: First group;Drug: Enoxaparin 40 mg 12 hours before arm<br>* Enoxaparin 40 mg 12 hours before surgery<br>* Other names: second group;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Venous thrombosis and/or pulmonary embolism (PE) | To assess the venous thrombosis by compression ultrasonography and PE in suspected patients | Postoperative 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bleeding from the surgery site , drain if any, GIT bleeding, | Bleeding from drain, GIT, or wounds are assessed clinically | postoperative 4 weeks | 
| hospital stay | hospital stay in days | 4 WEEKS | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Morbid obesity, Laparoscopic surgery, Compression ultrasonography, Pulmonary embolism, Bleeding
Clinical Comparison Between Two Surgical Techniques for the Treatment of Gingival Recessions

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to test a surgical technique for the treatment of gingival recessions. The hypothesis of the study is to promote greater root coverage and better healing.

Official Title
-----------------
Clinical Comparison Between Two Surgical Techniques With Acellular Dermal Matrix Graft in the Treatment of Gingival Recessions

Conditions
-----------------
Gingival Recession

Intervention / Treatment
-----------------
* Procedure: Periodontal surgery to gingival recessions


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Recession defects are Miller's class I or II and do not vary more or equal than 3 mm Main complaint aesthetic issues or dentine hypersensitivity The patient must be a candidate for bilateral root coverage procedure Patient shows sufficient plaque control (FMPS < 20%) The patient is able to comply with the study-related procedures such as exercising good oral hygiene and attending all follow-up procedures The patient is able to fully understand the nature of the proposed surgery and is able to provide a signed informed consent Exclusion Criteria: Smokers Systemic diseases Pregnants or lactating Periodontal disease General contraindications for dental and/or surgical treatment are present The patient has a history of malignancy, radiotherapy, or chemotherapy for malignancy within the past five years The patient is taking medications or having treatments which have an effect on mucosal healing in general (e.g. steroids, large doses of anti-inflammatory drugs)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: test and control<br>The test and control technique will be tested in a split-mouth design. | Procedure: Periodontal surgery to gingival recessions<br>* Test and control technique to treat gingival recessions.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of root coverage | Clinical parameters will be assessed after 6 months of surgical procedures. | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Keratinized Tissue | Clinical parameters will be assessed after 6 months of surgical procedures. | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
gingival recession, acellular dermal matrix graft, root coverage
The Influence of Cancer Stem-cells on Risk of Relapse in Patients Harboring Adenocarcinoma and Squamous Cell Carcinoma of the Lung

Study Overview
=================
Brief Summary
-----------------
The present study is a prospective cohort study. The aim is to assess the relationship between the presence of cancer stem-cells (CSC) and the risk of relapse in patients with early and locally advanced adenocarcinoma and squamous cell carcinoma of the lung

Official Title
-----------------
The Influence of Cancer Stem-cells on Risk of Relapse in Patients Harboring Adenocarcinoma and Squamous Cell Carcinoma of the Lung: a Prospective Cohort Study

Conditions
-----------------
Lung Cancer, Nonsmall Cell, Relapse/Recurrence, CSC

Intervention / Treatment
-----------------
* Genetic: Exposure to lung cancer stem cells


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with stage I, II or IIIA adenocarcinoma of squamous cell carcinoma of the lung age between 18 and 85 R0 resection availability of formalin-fixed, paraffin-embedded surgery specimen from the primary tumor availability of fresh surgical specimen for cytofluorimetric analysis Exclusion Criteria: incomplete resection unknown tumor, node or metastasis status synchronous tumors previous lung cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: Exposure to lung cancer stem cells|The exposure to lung cancer stem cells was measure as the percentage of Aldehyde dehydrogenase (ALDH) on all viable cells extracted from surgically resected tumor specimens|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relapse Free Survival | Days from lung cancer resection to relapse | Minimum follow-up time: 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Non Small Cell Lung Cancer, Cancer Stem Cells
Is There Any Relation Between Pain and Stone Location in Retrograde Intrarenal Surgery?

Study Overview
=================
Brief Summary
-----------------
We want to serach the relationship between the pain degree and stone localisation in kidney in Retrograde intrarenal surgery

Conditions
-----------------
Nephrolithiasis

Intervention / Treatment
-----------------
* Procedure: Retrograde Intrarenal Surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing RIRS Age between 18 and 90 years Exclusion Criteria: Patients who have congenital urogenital abnormalities 2)Patients who have previous surgery history

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: first group<br>patients who have upper pole kidney stones treated with flexible renoscopy | Procedure: Retrograde Intrarenal Surgery<br>* endoscopic treatment of kidney stones with flexible renoscopy<br>|
| Active Comparator: second group<br>patients u who have mid pole kidney stones treated with flexible renoscopy | Procedure: Retrograde Intrarenal Surgery<br>* endoscopic treatment of kidney stones with flexible renoscopy<br>|
| Active Comparator: third group<br>patients who have lower pole kidney stones treated with flexible renoscopy | Procedure: Retrograde Intrarenal Surgery<br>* endoscopic treatment of kidney stones with flexible renoscopy<br>|
| Active Comparator: forth group<br>patients who have kidney stones in pelvis treated with flexible renoscopy | Procedure: Retrograde Intrarenal Surgery<br>* endoscopic treatment of kidney stones with flexible renoscopy<br>|
| Active Comparator: fifth group<br>patients who have multiple calixes kidney stones treated with flexible renoscopy | Procedure: Retrograde Intrarenal Surgery<br>* endoscopic treatment of kidney stones with flexible renoscopy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain degree |  | Pain degree postoperative 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pain, RIRS, kidney
Clustering Among the Clinical Profiles of Patients With Pectus Excavatum

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study is to describe the relative distances between patient clinical profiles (i.e. patient clustering) in multivariate space.

Detailed Description
-----------------
Observational data will be collected from patient files and submitted to clustering analyses. Then clusters will be compared.

Official Title
-----------------
Clustering Among the Clinical Profiles of Patients With Pectus Excavatum

Conditions
-----------------
Funnel Chest

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patient with pectus excavatum The patient has had corrective surgery Exclusion Criteria: The patient has expressed opposition to the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| The study population<br>Patients with pectus excavatum having consulted at the Montpellier University Hospital and who have had corrective surgery. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of clusters found | The number of clusters found among clinical profiles | Day 0 (transversal, retrospective study) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pectus excavatum
Influence of Stroke on the Composition of Intestinal Microbiota

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to verify the hypothesis that the microbial colonisation of the gut is changed in patients after stroke and that the gut microbiome of severely affected stroke patients differs from that of patients with only a short disruption of blood circulation in the brain (transient ischemic attack, TIA). For this, the composition of gut microbiota in stool samples will be analyzed by 454 pyrosequencing. Further, the correlation of stroke-associated changes in the microbiome with immunological parameters will be analyzed.

Official Title
-----------------
Influence of Stroke on the Composition of Intestinal Microbiota (GUTSTROKE)

Conditions
-----------------
Stroke, Transient Ischemic Attack (TIA)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age: 18 and older ischemic cerebral infarction within the last 40 hours, anterior circulation infarct (ACA, MCA) and/or posterior circulation infarct (PCA, BA) of any severity patient consent or consent by a legal representative NIHSS > or =9 (stroke patients) NIHSS < 1 (for TIA patients) Exclusion Criteria: intracranial hemorrhage preexisting dysphagia signs of infection upon admission (clinical/paraclinical) existing antibiotic therapy upon admission or within the last 2 weeks before admission mechanical ventilation upon admission participation in an interventional therapy study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Stroke patients<br> | |
| TIA patients<br>patients with a transient ischemic attack (control group) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| composition of intestinal microbiome | The composition of the intestinal metagenome / microbiome will be determined by analyzing the 16S rRNA by 454 Pyrosequencing. | change between day 1, day 4, day 7, day 14 after stroke | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| test of correlation between most changed group of bacteria with changes in immunological parameters (HLA-DR) | Analysis of correlation between changes in microbiome (most changed group of bacteria, e.g. lactobacilli) with changes in immunological parameters (e.g. HLA-DR, IL-6, IL-10, CD4-lymphocytes from blood samples). | days 1, 4, 7 after stroke | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ischemia, stroke, transient ischemic attack (TIA), microbiome, microbiota, gut
IV Versus IM Administration of Oxytocin for Postpartum Bleeding

Study Overview
=================
Brief Summary
-----------------
This double-blind, randomized controlled trial will evaluate the effect of the route of administration of 10 IU of oxytocin on the average blood loss postpartum. Participants will be randomized to receive 10 IU of oxytocin by IV infusion or 10 IU of oxytocin by injection IM

Official Title
-----------------
Intravenous Versus Intramuscular Administration of Oxytocin and Its Relationship With Postpartum Bleeding and Other Clinical Signs: a Randomized Placebo-controlled Study

Conditions
-----------------
Postpartum Hemorrhage

Intervention / Treatment
-----------------
* Drug: IV Oxytocin + IM placebo
* Drug: IM Oxytocin + IV placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: She is present to give birth to a live fetus Vaginal delivery Willing to participate in the study Able to give informed consent Exclusion Criteria: Scheduled for a cesarean Reject the placement of an IV during labor (for intravenous infusion) Cannot give informed consent for any reason Not willing and / or cannot answer questions about background
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: IV Infusion<br>Oxytocin 10 IU, 500 ml IV infusion within 40 minutes + intra muscular injection of placebo, 10 IU | Drug: IV Oxytocin + IM placebo<br> <br> |
| Active Comparator: IM administration<br>Oxytocin 10 IU via intra muscular injection + Intravenously administered placebo, 10 IU, 500ml | Drug: IM Oxytocin + IV placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Amount of blood loss (mL) |  | 1 hour postpartum | 
| Proportion of women who had postpartum blood loss ≥500 ml |  | 1 hour postpartum | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of women who had postpartum blood loss ≥1000 ml |  | 1 hour postpartum | 
| Average change in hemoglobin level |  | pre-delivery and at least 24 hours postpartum | 
| Average time required until expulsion of the placenta |  | 1 hour postpartum | 
| Proportion who needed additional Interventions |  | Through study completion, an average of 24-48 hours postpartum | 
| Side effects |  | 1 hour postpartum | 
| Blood pressure |  | 15, 30, 45 and 60 minutes postpartum | 
| Heart rate |  | 15, 30, 45 and 60 minutes postpartum | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Oxytocin